» Satralizumab Reduces Risk of Severe NMOSD Relapse

.bg-primary, .bg-primary:hover,.bg-primary:focus, a.bg-primary:focus, a.bg-primary:hover, button.bg-primary:focus, button.bg-primary:hover, .badge-primary { background:#D7300B !important; } .btn-primary, .btn-primary:hover { color: #fff; background-color: #D7300B !important; border-color: #D7300B !important; } .text-primary, .filters_col .distance span { color: #D7300B !important; } .btn-outline-primary { color: #D7300B !important; border-color: #D7300B !important; } .btn-outline-primary:hover { background:none !important; } .text-primary a { color: #D7300B !important; } .bg-secondary, .bg-secondary:hover, .bg-secondary:focus, a.bg-secondary:focus, a.bg-secondary:hover, button.bg-secondary:focus, button.bg-secondary:hover, .irs-bar { background-color:#111111 !important; } .btn-secondary, .btn-secondary:hover, .btn-secondary:focus { color: #fff; background-color: #111111 !important; border-color: #111111 !important; } .text-secondary { color: #111111 !important; } .text-secondary a { color: #111111 !important; } .btn-outline-secondary { color: #111111 !important; border-color: #111111 !important; } .btn-outline-secondary:hover { background:none !important; }

Satralizumab Reduces Risk of Severe NMOSD Relapse

Title

$0